TREATMENT READING
Breast Cancer Treatment During Pregnancy (PDQ®)
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Treating breast cancer during pregnancy
Source: Breast Cancer During Pregnancy, National Cancer Institute.
Source updated: December 2, 2025. Captured 2026-09-09.
Treating breast cancer during pregnancy
Treatment options for pregnant women depend on the stage of the disease and the trimester of the pregnancy.
Pregnant women with early-stage breast cancer (stage I and stage II) are usually treated in the same way as women who are not pregnant, with some changes in the timing of certain treatments to protect the fetus. Treatment may be more complicated in pregnant women with late-stage breast cancer (stage III and stage IV) because some treatments may need to begin quickly and could harm the fetus. Ending a pregnancy may be considered if the cancer is fast-growing or advanced and treatment is needed right away. The ability to safely terminate a pregnancy because of an advanced cancer diagnosis may vary based on your state of residence.
Sources: advanced cancer
Treatment for breast cancer during pregnancy may include:
Surgery. Most pregnant women with breast cancer have a lumpectomy, also called breast-conserving surgery, or a modified radical mastectomy to remove the breast. Some of the lymph nodes under the arm may be removed so a pathologist can check them under a microscope for signs of cancer. If surgery is planned and the woman has already given birth, breastfeeding should be stopped to reduce blood flow in the breasts and make them smaller. Learn more about Breast Cancer Surgery, including reconstruction.
Sources: lumpectomy · modified radical mastectomy · lymph nodes · pathologist · Breast Cancer Surgery
Chemotherapy. After the first 3 months of pregnancy, certain types of chemotherapy may be given before or after surgery. Chemotherapy given at this time does not usually harm the fetus but may cause early labor or low birth weight. Chemotherapy also should be avoided 3 to 4 weeks before delivery, because it can cause delivery complications for both the mother and baby. Women receiving chemotherapy should not breastfeed. Many chemotherapy drugs may be found in high levels in breast milk and could harm the nursing baby. Learn more about Chemotherapy for Breast Cancer.
Sources: Chemotherapy for Breast Cancer
Radiation therapy. Delaying radiation therapy until after the baby is born is usually the safest option. Women with late-stage breast cancer (stage III or stage IV) may consider external radiation therapy after a careful assessment of the risks and benefits. Talk with your doctor about the risks and benefits of radiation therapy as you discuss your treatment plan. Learn more about Radiation for Breast Cancer.
Sources: treatment plan · Radiation for Breast Cancer
Other treatments. Hormone therapy, targeted therapy, and immunotherapy are usually not given to pregnant or nursing women because these treatments are harmful to a fetus or a nursing baby.
Sources: targeted therapy · immunotherapy
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
General Information About Breast Cancer Treatment During Pregnancy
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
Incidence
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
Breast cancer is the most common cancer in pregnant and postpartum women and occurs in about 1 in 3,000 pregnant women. The average patient is between the ages of 32 years and 38 years. Because many women are choosing to delay childbearing, it is likely that the incidence of breast cancer during pregnancy will increase.
Anatomy
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
Diagnostic Evaluation
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
The natural tenderness and engorgement of the breasts of pregnant and lactating women may hinder detection of discrete masses and early diagnosis of breast cancer. Delays in diagnosis are common, with an average reported delay of 5 to 15 months from the onset of symptoms.[1-4] Because of this delay, cancers are typically detected at a later stage than in a nonpregnant, age-matched population.[5]
The following tests and procedures may be used to diagnose breast cancer during pregnancy:
Breast self-examination.
Clinical breast examination.
Ultrasound.
Biopsy and hormone receptor assays.
Mammography.
To detect breast cancer, pregnant and lactating women should consider practicing self-examination and undergo a clinical breast examination as part of the routine prenatal examination by a doctor. If an abnormality is found, diagnostic approaches such as ultrasound and mammography may be used. With proper shielding, mammography poses little risk of radiation exposure to the fetus.[6] However, mammograms are only used to evaluate dominant masses and to locate occult carcinomas in the presence of other suspicious physical findings.[6]
Because at least 25% of mammograms in pregnancy may be negative in the presence of cancer, a biopsy is essential for the diagnosis of any palpable mass. Diagnosis may be safely accomplished with a fine-needle aspiration, core biopsy, or excisional biopsy under local anesthesia. To avoid a false-positive diagnosis as a result of misinterpretation of pregnancy-related changes, the pathologist should be advised that the patient is pregnant.[7]
Sources: 7
Breast cancer pathology is similar in age-matched pregnant and nonpregnant women. Hormone receptor assays using a competitive binding assay are usually negative in pregnant patients with breast cancer, but this may be the result of receptor binding by high serum estrogen levels associated with the pregnancy. Enzyme immunocytochemical receptor assays are more sensitive than competitive binding assays. A study that used both assay methods indicated similar receptor positivity between pregnant and nonpregnant women with breast cancer.[8] The study concluded that increased estrogen levels during pregnancy could result in a higher incidence of receptor positivity detected with immunohistochemistry than is detected by radiolabeled ligand-binding assay because of competitive inhibition by high levels of endogenous estrogen.
Sources: 8
For more information, see the Diagnosis section in Breast Cancer Treatment.
Sources: Diagnosis
Prognosis
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
The overall survival of pregnant women with breast cancer may be worse than that of nonpregnant women at all stages.[6] However, this discrepancy may be primarily the result of delayed diagnosis.[9] Termination of pregnancy has not shown any beneficial effect on breast cancer outcome and is not usually considered as a therapeutic option.[1,2,4,10,11]
Stage Information for Breast Cancer Treatment and Pregnancy
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
Staging Evaluation
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
The following procedures are used to determine the extent of the cancer:
Chest x-ray.
Bone scan.
Ultrasound of the liver.
Magnetic resonance imaging (MRI) of the brain.
Procedures used for determining the stage of breast cancer are modified for pregnant women to avoid radiation exposure to the fetus. Nuclear scans cause fetal radiation exposure.[1] If such scans are essential for evaluation, hydration and Foley catheter drainage of the bladder can be used to prevent retention of radioactivity. Timing of the exposure to radiation relative to the gestational age of the fetus may be more critical than the actual dose of radiation delivered.[2] Radiation exposure during the first trimester (>0.1 Gy) may lead to congenital malformations, intellectual disability, and increased relative risk of carcinogenesis.
Chest x-rays with abdominal shielding are considered safe, but as with all radiological procedures, they are used only when essential for making treatment decisions.[1,3] A chest x-ray delivers 0.00008 Gy.[4]
For the diagnosis of bone metastases, a bone scan is preferable to a skeletal series because the bone scan delivers a smaller amount of radiation and is more sensitive. A bone scan delivers 0.001 Gy.[5]
Sources: 5
Evaluation of the liver can be performed with ultrasound, and brain metastases can be diagnosed with an MRI scan. Data on MRI during pregnancy are not available, but gadolinium crosses the placenta and is associated with fetal abnormalities in rats.[5]
Sources: 5
American Joint Committee on Cancer (AJCC) Stage Groupings and Definitions of TNM
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
For more information, see the Stage Information for Breast Cancer section in Breast Cancer Treatment.
Sources: Stage Information for Breast Cancer
Treatment of Early/Localized/Operable Breast Cancer During Pregnancy
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
Generally, pregnant women with stage I or stage II breast cancer are treated in the same way as nonpregnant patients, with some modifications to protect the fetus.
Treatment options for early/localized/operable breast cancer in pregnant women include:
Surgery. Postpartum radiation therapy may also be given to women diagnosed with breast cancer late in pregnancy.
Sources: Surgery
Chemotherapy (after the first trimester).
Sources: Chemotherapy
Endocrine therapy (after delivery).
Sources: Endocrine therapy
The use of trastuzumab during pregnancy is contraindicated.
Sources: trastuzumab
Surgery
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
Surgery is recommended as the primary treatment of breast cancer in pregnant women.
The data regarding safety of sentinel lymph node biopsy in pregnant patients are limited to several retrospective case series. One study examined sentinel lymph node biopsy in eight patients in the first trimester, nine patients in the second trimester, and eight patients in the third trimester. Technetium Tc 99m alone was used in 16 patients, methylene blue dye alone was used in seven patients, and two patients had unknown mapping methods. All 25 patients had live-born infants, of whom 24 were healthy, and one had a cleft palate (in the setting of other maternal risk factors).[1]
Sources: 1
Because radiation in therapeutic doses may expose the fetus to potentially harmful scatter radiation,[2] modified radical mastectomy is the treatment of choice if the breast cancer was diagnosed early in pregnancy. If diagnosed late in pregnancy, breast-conserving surgery with postpartum radiation therapy has been used for breast preservation.[3] An analysis has been performed that helps to predict the risk of waiting to have radiation.[4,5]
Chemotherapy
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
Data suggest that it is safe to administer certain chemotherapeutic drugs after the first trimester, with most pregnancies resulting in live births with low rates of morbidity in the newborns.
Anthracycline-based chemotherapy (doxorubicin plus cyclophosphamide or fluorouracil, doxorubicin, and cyclophosphamide [FAC]) appears to be safe to administer during the second and/or third trimester on the basis of limited prospective data.[6-8] Safety data on the use of taxanes during pregnancy are limited.
Evidence (use of chemotherapy during the second and/or third trimester of pregnancy):
A multicenter case-control study compared pediatric outcomes of 129 children whose mothers had breast cancer with matched children of women without cancer. In the pregnancy study group, 96 children (74.4%) were exposed to chemotherapy, 11 (8.5%) to radiation therapy, 13 (10.1%) to surgery alone, 2 (1.7%) to other drug treatments, and 14 (10.9%) to no treatment.[9]
Sources: 9
A multicenter case-control study compared pediatric outcomes of 129 children whose mothers had breast cancer with matched children of women without cancer. In the pregnancy study group, 96 children (74.4%) were exposed to chemotherapy, 11 (8.5%) to radiation therapy, 13 (10.1%) to surgery alone, 2 (1.7%) to other drug treatments, and 14 (10.9%) to no treatment.[9]
The study showed that there was no significant difference in birth weight below the 10th percentile (22% in the breast cancer treatment‒exposed group vs. 15.2% in the control group, P = .16) or in cognitive development based on the Bayley score (P = .08). The gestational age at birth was correlated with cognitive outcome in the two study groups.
Evaluation of cardiac function among 47 children, who were age 36 months in the study group, showed normal cardiac findings.
In a prospective single-arm study, 57 pregnant patients with breast cancer were treated with FAC in the adjuvant or neoadjuvant setting.[6]
Sources: 6
In a prospective single-arm study, 57 pregnant patients with breast cancer were treated with FAC in the adjuvant or neoadjuvant setting.[6]
Survey data collected when the children were aged 2 months to 157 months revealed that no stillbirths, miscarriages, or perinatal deaths occurred.
One child born vaginally at a gestational age of 38 weeks had a subarachnoid hemorrhage on day 2 postpartum, one child had Down syndrome, and two children had congenital anomalies (club foot and bilateral ureteral reflux).
The findings of the prospective single-arm study above were consistent with other smaller retrospective series of anthracycline-based chemotherapy.[7,8]
A systematic review studied 40 case reports of taxane administration during the second or third trimesters of pregnancy.[10]
Sources: 10
A systematic review studied 40 case reports of taxane administration during the second or third trimesters of pregnancy.[10]
Minimal maternal, fetal, or neonatal toxicity was observed.
Fluorouracil dosing
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[11,12] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[11-13] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[14-16] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[17] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[18]
Endocrine Therapy
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
Endocrine therapy is generally avoided until after delivery. Case reports and a literature review of tamoxifen during pregnancy show that tamoxifen administration during pregnancy is associated with vaginal bleeding, miscarriage, congenital abnormalities such as Goldenhar syndrome, and fetal death.[19-21] Breastfeeding is also not recommended concurrently with endocrine therapy.[22]
Targeted Therapy
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
The use of trastuzumab during pregnancy is contraindicated based on results of a systematic review of 17 studies (18 pregnancies, 19 newborns).[23] Of the fetal complications noted, occurrence of oligohydramnios/anhydramnios was the most common (61.1%) adverse event. Of the pregnancies exposed to trastuzumab during the second or third trimester, 73.3% of the pregnancies were complicated with oligohydramnios/anhydramnios. Of the pregnancies exposed to trastuzumab exclusively during the first trimester, 0% (P = .043) of the pregnancies were complicated with oligohydramnios/anhydramnios. The mean gestational age at delivery was 33.8 weeks, and the mean weight of newborns at delivery was 2,261 grams or 4.984 pounds. In 52.6% of cases, a healthy neonate was born. At the long-term evaluation, all children who were without complications at birth were healthy, with a median follow-up of 9 months, and four of nine children with complications at birth had died within an interval ranging from birth to 5.25 months. All children exposed to trastuzumab in utero exclusively in the first trimester were completely healthy at birth. The data suggest that for women who become pregnant during trastuzumab administration and wish to continue pregnancy, trastuzumab should be stopped and pregnancy would be allowed to continue.
Sources: 23
Treatment of Advanced Breast Cancer During Pregnancy
Source: Breast Cancer Treatment During Pregnancy (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 4, 2024. Captured 2026-09-09.
There is no standard treatment for patients with advanced (stage III or stage IV) breast cancer during pregnancy. Most studies show a 5-year survival rate of 10% in pregnant patients with stage III or IV disease.
First-trimester radiation therapy should be avoided. Chemotherapy may be given after the first trimester as discussed in the section on Treatment of Early/Localized/Operable Breast Cancer During Pregnancy.
Sources: Treatment of Early/Localized/Operable Breast Cancer During Pregnancy
Because the mother's life span may be limited, and there is a risk of fetal damage with treatment during the first trimester,[1,2] issues regarding continuation of the pregnancy should be discussed with the patient and her family. Therapeutic abortion does not improve prognosis.[1-5]
Triangle